Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2003
04/17/2003WO2003031552A1 Decontamination of surfaces contaminated with prion-infected material with oxidizing agent-based formulations
04/17/2003WO2003031551A1 Decontamination of surfaces contaminated with prion-infected material with gagseous oxidizing agents
04/17/2003WO2003031476A1 Antibody of human origin for inhibiting thrombocytes aggregation
04/17/2003WO2003031459A2 Modulation of the expression of genes dependent on stat-1
04/17/2003WO2003031449A2 Cross-linked glycopeptide-cephalosporin antibiotics
04/17/2003WO2003031448A1 Reverse-turn mimetics and method relating thereto
04/17/2003WO2003031447A2 Pyrimidine derivatives
04/17/2003WO2003031446A1 Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
04/17/2003WO2003031445A1 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
04/17/2003WO2003031444A1 Polycyclic compounds having anti-tumor activity
04/17/2003WO2003031443A1 Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
04/17/2003WO2003031442A1 Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
04/17/2003WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003WO2003031439A1 Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
04/17/2003WO2003031438A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
04/17/2003WO2003031437A1 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
04/17/2003WO2003031436A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract
04/17/2003WO2003031434A1 Compounds and methods
04/17/2003WO2003031432A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
04/17/2003WO2003031422A1 Novel benzothiazine derivatives, their preparation and use
04/17/2003WO2003031418A1 3,4-dihydro-1h-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor
04/17/2003WO2003031416A2 [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
04/17/2003WO2003031415A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
04/17/2003WO2003031414A1 Novel heterocyclic compound and anti-inflammatory agent
04/17/2003WO2003031413A1 Quinoline derivatives, synthesis method, and medicines containing said derivatives
04/17/2003WO2003031412A1 Piperidine compounds as muscarinic antagonists
04/17/2003WO2003031410A1 Ligands of melanocortin receptors and compositions and methods related thereto
04/17/2003WO2003031409A1 1h-indole derivatives as a highly selective cyclooxygenase-2 inhibitor
04/17/2003WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
04/17/2003WO2003031406A2 Kinase inhibitor scaffolds and methods for their preparation
04/17/2003WO2003031405A2 Methods for the synthesis of substituted purines
04/17/2003WO2003031404A2 Processes for the preparation of substituted isoxazoles and 2-isoxazolines
04/17/2003WO2003031400A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3
04/17/2003WO2003031398A1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
04/17/2003WO2003031397A1 Acylsulfonamides as inhibitors of steroid sulfatase
04/17/2003WO2003031396A1 Salts of guanidine derivatives and pharmaceutical preparations consisting thereof
04/17/2003WO2003031394A1 Organic compounds
04/17/2003WO2003031393A2 Carbonyloxy-cyanomethyl compounds as antiparasitic agents
04/17/2003WO2003031381A2 Synthesis of (z)-3,5,4'-trimethoxystilbene, and use thereof
04/17/2003WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003WO2003030953A1 Inhibition of exoprotein production using aromatic compositions
04/17/2003WO2003030947A2 Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions
04/17/2003WO2003030944A2 Inhibition of stat-1
04/17/2003WO2003030942A1 Pharmaceutical formulation
04/17/2003WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003WO2003030939A1 Therapies for treating respiratory diseases
04/17/2003WO2003030938A1 Immunotherapeutics for cancer
04/17/2003WO2003030937A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
04/17/2003WO2003030935A2 Adjuvants for nucleic acid vaccines
04/17/2003WO2003030934A2 Cpg formulations and related methods
04/17/2003WO2003030929A1 Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
04/17/2003WO2003030928A2 Antitumor preparation
04/17/2003WO2003030922A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
04/17/2003WO2003030920A1 An antispasmodic agent spaced drug delivery system
04/17/2003WO2003030916A1 Medical and nutritional applications of highly refined cellulose
04/17/2003WO2003030915A1 Use of solamargine for treating skin tumors
04/17/2003WO2003030914A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs)
04/17/2003WO2003030912A1 Prostaglandin analogs as chloride channel opener
04/17/2003WO2003030911A1 Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
04/17/2003WO2003030910A1 Pharmaceutical composition for the treatment of disorders of non-human mammals
04/17/2003WO2003030908A2 Inhibitors of the egf receptor for the treatment of thyroid cancer
04/17/2003WO2003030906A1 Treating infections by administration of oxazolidinones to the skin
04/17/2003WO2003030904A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
04/17/2003WO2003030903A1 The use of tizanidine for treating metabolic disorders related to abnormal insulin secretion
04/17/2003WO2003030902A1 Imidazole derivates as anti-inflammatory agents
04/17/2003WO2003030901A1 Arylsulphonyl-substituted tetrahydro- and hexahydro-carbazoles as 5-ht-6 receptor ligands
04/17/2003WO2003030900A1 Remedies for attention-deficient/hyperreactivity disorder
04/17/2003WO2003030899A2 Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
04/17/2003WO2003030897A1 Pyrrolidinone derivatives
04/17/2003WO2003030896A1 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same
04/17/2003WO2003030895A1 Styryl acrylonitrile compounds and their use to promote myelopoiesis
04/17/2003WO2003030894A1 Methods for treating dry eye
04/17/2003WO2003030893A1 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
04/17/2003WO2003030892A1 Methods for treating dry eye
04/17/2003WO2003030891A1 Use of hydroxyoleic acid and similar compounds in the production of medicaments
04/17/2003WO2003030890A1 Immune system activators
04/17/2003WO2003030889A1 Para-amino benzoic acids as integrin antagonists
04/17/2003WO2003030888A1 Antiradicals and fat compositions, foods, drinks, drugs or feeds containing the antiradicals
04/17/2003WO2003030887A1 Composition and method for improving sexual desire and erectile function
04/17/2003WO2003030886A2 Allylamides useful in the treatment of alzheimer's disease
04/17/2003WO2003030884A2 Use of solasonine for the treatment of skin tumors
04/17/2003WO2003030882A1 Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made thereform
04/17/2003WO2003030880A1 Transdermal delivery devices
04/17/2003WO2003030878A2 Galenic microparticulate oral formulation
04/17/2003WO2003030877A1 Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer
04/17/2003WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003WO2003030871A1 Powder processing with pressurized gaseous fluids
04/17/2003WO2003030869A1 Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
04/17/2003WO2003030867A2 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid
04/17/2003WO2003030864A1 Liposomal formulation of irinotecan
04/17/2003WO2003030862A2 Anaesthetic compositions and method for their administration
04/17/2003WO2003030860A1 Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof
04/17/2003WO2003030857A1 Enhancing epidermal barrier development in skin
04/17/2003WO2003030844A1 Long-acting hair growth stimulant preparations
04/17/2003WO2003030832A2 Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
04/17/2003WO2003030827A2 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003WO2003030826A2 Antisense modulation of insulin-like growth factor binding protein 5 expression
04/17/2003WO2003030824A2 Methods and compositions for treating dermal lesions
04/17/2003WO2003030823A2 Combinations for the treatment of immunoinflammatory disorders
04/17/2003WO2003030822A2 Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
1 ... 5496 5497 5498 5499 5500 5501 5502 5503 5504 5505 5506 5507 5508 5509 5510 5511 5512 5513 5514 5515 5516 ... 7860